In addition to putting carriers at increased risk for breast and ovarian cancers, BRCA2 germline mutations carriers are also at increased risk for pediatric and adolescent non-Hodgkin lymphoma (NHL), according to data from the SJLIFE study.

Prior
data from the study showed that BRCA2 was the third most frequently
mutated gene among 3006 survivors of childhood cancers, with the highest
incidence among survivors of lymphoma. To investigate this connection further,
researchers conducted whole-genome sequencing on 1380 5-year survivors of
pediatric or adolescent lymphomas. Median age at diagnosis was 13.4 years.

Among
these survivors, 12 pathogenic or likely pathogenic BRCA2 mutations were
identified, a rate of 0.6% among Hodgkin lymphoma survivors and 1.4% among NHL
survivors. All 8 survivors of NHL with a BRCA2 mutation were male.

Compared
with a group of controls without cancer, survivors with BRCA2 mutations
were at more than 3 times the risk for lymphoma (odds ratio, 3.3; 95% CI,
1.7-5.8). When looked at by specific diagnosis, only the association between
the aberration and NHL was statistically significant (OR, 5.0; 95% CI,
2.1-10.2).

When
family histories were obtained for 7 of the 8 NHL survivors with BRCA2
mutations, 6 were found to have family histories of breast, prostate, and
pancreatic cancers, as well as melanoma.

“Genetic
counseling and the option of BRCA2 genetic testing should be offered to
survivors of pediatric or adolescent non–Hodgkin lymphoma, particularly those
with a family history of BRCA2-associated cancers,” the researchers
wrote. “Survivors whose test results are positive for mutation should be
offered surveillance for BRCA2-associated cancers, such as breast and
ovarian, and counseled about cancer risk–reducing strategies.”

Reference

Wang Z, Wilson CL, Armstrong GT, et al. Association of germline BRCA2 mutations with the risk of pediatric of adolescent non-Hodgkin lymphoma [published online July 25, 2019]. JAMA Oncol. doi: 10.1001/jamaoncol.2019.2203

This article originally appeared on Cancer Therapy Advisor